Furthermore, we have shown expression of COL8A1, COL11A1, BGN, SORCS2, POSTN and COL6A5 to be increased in CAS of malignant CMTs compared to benign adenomas on both the RNA and protein level, and high expression of COL6A5 and POSTN to correlate with significantly lower overall survival in human breast cancer patients [13]. This evidence concerns the gene SORCS2 and breast cancer.